Berlin - Delayed Quote EUR

Lonza Group Ltd (LO3A.BE)

61.00

+0.50

+(0.83%)

At close: April 25 at 5:20:04 PM GMT+2

Health Care Roundup: Market Talk

Find insight on Hims & Hers, U.K. pharmaceutical stocks, Novo Nordisk, AstraZeneca and more in the latest Market Talks covering the Health Care sector.

The Wall Street Journal 23 days ago

LZAGF
+3.93%
LZAGY
+0.01%
SGFEF
Boehringer Ingelheim broadens oncology portfolio with license for Synaffix's ADC technology

Boehringer Ingelheim and Synaffix B.V. ("Synaffix"), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of best-in-class antibody-drug conjugates (ADCs), today announced that Boehringer has licensed Synaffix's ADC technology. This new partnership significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company's aim of transforming the lives of people with cancer.

PR Newswire 3 months ago

LZAGF
+3.93%
LZAGY
+0.01%
Synaffix and Mitsubishi Tanabe Pharma Sign License Agreement for ADC Technology

Synaffix B.V. ("Synaffix"), a Lonza company (SWX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announced that it has licensed its ADC technology to Mitsubishi Tanabe Pharma Corporation ("MTPC"), the pharma arm of Mitsubishi Chemical Group ("MCG").

PR Newswire 3 months ago

LZAGF
+3.93%
LZAGY
+0.01%
Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion

Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that it has entered into a licensing agreement with Elevation Oncology, Inc., an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs.

PR Newswire 4 months ago

LZAGF
+3.93%
LZAGY
+0.01%
Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors

Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the nomination of EO-1022 as its HER3 ADC development candidate. EO-1022 is currently progressing through preclinical development, and Elevation Oncology expects to file an investigational new drug (IND) application in 2026.

PR Newswire 4 months ago

LZAGF
+3.93%
LZAGY
+0.01%
ELEV
Lonza's Synaffix Collaborates with BigHat Biosciences on the Development of a Machine Learning-Designed ADC

Synaffix B.V. ("Synaffix"), a Lonza company (SWX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announced that it has licensed its ADC technology to BigHat Biosciences, Inc. ("BigHat"). BigHat will combine Synaffix technology with its world-class ML antibody design platform for the development of a new ADC pipeline program.

PR Newswire 5 months ago

LZAGF
+3.93%
LZAGY
+0.01%
NeuroSense Announces First Quarter 2024 Business Update

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.

PR Newswire 11 months ago

LZAGF
+3.93%
LZAGY
+0.01%
NRSN

Performance Overview

Return	LO3A.BE	MSCI WORLD (^990100-USD-STRD)
YTD	+7.02%	-2.70%
1-Year	+15.00%	+8.88%
3-Year	+3.82%	--

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Lonza Group Ltd (LO3A.BE)

Health Care Roundup: Market Talk

Boehringer Ingelheim broadens oncology portfolio with license for Synaffix's ADC technology

Synaffix and Mitsubishi Tanabe Pharma Sign License Agreement for ADC Technology

Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion

Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors

Lonza's Synaffix Collaborates with BigHat Biosciences on the Development of a Machine Learning-Designed ADC

NeuroSense Announces First Quarter 2024 Business Update

Performance Overview